S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
CVE:KSI

kneat.com Competitors

C$3.03
-0.12 (-3.81 %)
(As of 03/5/2021 03:59 PM ET)
Add
Compare
Today's Range
C$2.97
Now: C$3.03
C$3.21
50-Day Range
C$2.37
MA: C$2.81
C$3.31
52-Week Range
C$1.05
Now: C$3.03
C$3.45
Volume69,145 shs
Average Volume109,800 shs
Market CapitalizationC$204.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

kneat.com (CVE:KSI) Vs. BU, APS, NRI, RIV, BLU, and TH

Should you be buying KSI stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to kneat.com, including Burcon NutraScience (BU), Aptose Biosciences (APS), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), Canopy Rivers (RIV), BELLUS Health (BLU), and Theratechnologies (TH).

kneat.com (CVE:KSI) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares kneat.com and Burcon NutraScience's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
kneat.comC$7.42 million27.52C$-5,797,862.00C($0.09)-35.23
Burcon NutraScienceC$12,045.0035,744.79C$107,101.00C$0.004,020.00

Burcon NutraScience has lower revenue, but higher earnings than kneat.com. kneat.com is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares kneat.com and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
kneat.comN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for kneat.com and Burcon NutraScience, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
kneat.com00103.00
Burcon NutraScience00103.00

kneat.com currently has a consensus target price of C$2.75, suggesting a potential downside of 9.24%. Burcon NutraScience has a consensus target price of C$5.00, suggesting a potential upside of 24.38%. Given Burcon NutraScience's higher probable upside, analysts clearly believe Burcon NutraScience is more favorable than kneat.com.

Summary

Burcon NutraScience beats kneat.com on 5 of the 6 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and kneat.com (CVE:KSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Valuation and Earnings

This table compares Aptose Biosciences and kneat.com's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.65)-7.35
kneat.comC$7.42 million27.52C$-5,797,862.00C($0.09)-35.23

Aptose Biosciences has higher earnings, but lower revenue than kneat.com. kneat.com is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Aptose Biosciences and kneat.com, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
kneat.com00103.00

Aptose Biosciences presently has a consensus price target of C$12.00, indicating a potential upside of 151.57%. kneat.com has a consensus price target of C$2.75, indicating a potential downside of 9.24%. Given Aptose Biosciences' higher possible upside, equities research analysts plainly believe Aptose Biosciences is more favorable than kneat.com.

Profitability

This table compares Aptose Biosciences and kneat.com's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
kneat.comN/AN/AN/A

Summary

Aptose Biosciences beats kneat.com on 3 of the 5 factors compared between the two stocks.

kneat.com (CVE:KSI) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Profitability

This table compares kneat.com and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
kneat.comN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for kneat.com and Nuvo Pharmaceuticals Inc. (NRI.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
kneat.com00103.00
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

kneat.com presently has a consensus price target of C$2.75, indicating a potential downside of 9.24%. Given kneat.com's higher possible upside, analysts plainly believe kneat.com is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Valuation & Earnings

This table compares kneat.com and Nuvo Pharmaceuticals Inc. (NRI.TO)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
kneat.comC$7.42 million27.52C$-5,797,862.00C($0.09)-35.23
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million0.14C$-6,980,844.00C($0.61)-1.48

kneat.com has higher earnings, but lower revenue than Nuvo Pharmaceuticals Inc. (NRI.TO). kneat.com is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals Inc. (NRI.TO), indicating that it is currently the more affordable of the two stocks.

Summary

kneat.com beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 4 of the 6 factors compared between the two stocks.

Canopy Rivers (TSE:RIV) and kneat.com (CVE:KSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Profitability

This table compares Canopy Rivers and kneat.com's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy RiversN/AN/AN/A
kneat.comN/AN/AN/A

Earnings & Valuation

This table compares Canopy Rivers and kneat.com's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy RiversC$15.44 million25.74C$-106,223,568.00C($0.76)-3.74
kneat.comC$7.42 million27.52C$-5,797,862.00C($0.09)-35.23

kneat.com has lower revenue, but higher earnings than Canopy Rivers. kneat.com is trading at a lower price-to-earnings ratio than Canopy Rivers, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Canopy Rivers and kneat.com, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Rivers01002.00
kneat.com00103.00

Canopy Rivers currently has a consensus target price of C$4.00, suggesting a potential upside of 40.85%. kneat.com has a consensus target price of C$2.75, suggesting a potential downside of 9.24%. Given Canopy Rivers' higher possible upside, equities research analysts plainly believe Canopy Rivers is more favorable than kneat.com.

Summary

kneat.com beats Canopy Rivers on 5 of the 8 factors compared between the two stocks.

kneat.com (CVE:KSI) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Valuation and Earnings

This table compares kneat.com and BELLUS Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
kneat.comC$7.42 million27.52C$-5,797,862.00C($0.09)-35.23
BELLUS HealthC$15,000.0025,328.96C$-42,145,306.00C($0.54)-9.01

kneat.com has higher revenue and earnings than BELLUS Health. kneat.com is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares kneat.com and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
kneat.comN/AN/AN/A
BELLUS HealthN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for kneat.com and BELLUS Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
kneat.com00103.00
BELLUS Health01202.67

kneat.com currently has a consensus price target of C$2.75, suggesting a potential downside of 9.24%. Given kneat.com's stronger consensus rating and higher probable upside, research analysts plainly believe kneat.com is more favorable than BELLUS Health.

Summary

kneat.com beats BELLUS Health on 5 of the 8 factors compared between the two stocks.

Theratechnologies (TSE:TH) and kneat.com (CVE:KSI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Theratechnologies and kneat.com's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
kneat.comN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Theratechnologies and kneat.com, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
kneat.com00103.00

Theratechnologies presently has a consensus target price of C$3.75, suggesting a potential downside of 5.06%. kneat.com has a consensus target price of C$2.75, suggesting a potential downside of 9.24%. Given Theratechnologies' higher possible upside, research analysts clearly believe Theratechnologies is more favorable than kneat.com.

Valuation and Earnings

This table compares Theratechnologies and kneat.com's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$63.33 million5.85C$-28,715,346.00C($0.31)-12.91
kneat.comC$7.42 million27.52C$-5,797,862.00C($0.09)-35.23

kneat.com has lower revenue, but higher earnings than Theratechnologies. kneat.com is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

kneat.com beats Theratechnologies on 5 of the 8 factors compared between the two stocks.


kneat.com Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BU
Burcon NutraScience
1.4$4.02-3.0%C$430.55 millionC$12,045.004,020.00
APS
Aptose Biosciences
1.3$4.77-2.1%C$423.87 millionN/A-7.35Gap Down
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$0.91-4.4%C$398.30 millionC$76.09 million-1.48Gap Up
RIV
Canopy Rivers
0.8$2.84-7.4%C$397.46 millionC$15.44 million-3.74Gap Up
BLU
BELLUS Health
0.5$4.85-2.3%C$379.93 millionC$15,000.00-9.01
Theratechnologies logo
TH
Theratechnologies
0.7$3.95-1.5%C$370.67 millionC$63.33 million-12.91
CRH Medical logo
CRH
CRH Medical
0.7$4.88-0.2%C$349.21 millionC$99.76 million-84.14Upcoming Earnings
AKU
Akumin
0.7$4.57-2.4%C$321.06 millionC$269.04 million-228.50
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5$13.60-0.2%C$315.66 millionC$39.91 million-0.22
NEPT
Neptune Wellness Solutions
1.2$1.78-0.6%C$294.58 millionC$52.78 million-1.32Gap Up
IMV logo
IMV
IMV
1.0$4.06-0.5%C$272.40 millionC$36,000.00-6.77
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89
FRX
Fennec Pharmaceuticals
0.5$9.28-1.5%C$239.52 millionN/A-11.15Upcoming Earnings
High Trading Volume
TMD
Titan Medical
0.8$2.17-2.8%C$237.67 millionC$20 million-6.01
MDNA
Medicenna Therapeutics
0.5$4.46-6.1%C$235.94 millionN/A-14.43
ICC
ICC Labs
0.5$1.62-6.2%C$228.24 millionC$533,684.0095.29Gap Down
Medical Facilities Co. (DR.TO) logo
DR
Medical Facilities Co. (DR.TO)
1.6$7.23-1.8%C$224.90 millionC$370.70 million10.03Upcoming Earnings
RVX
Resverlogix Corp. (RVX.TO)
0.7$0.96-5.2%C$224.63 millionN/A53.33Upcoming Earnings
ATE
Antibe Therapeutics
1.3$4.68-0.9%C$212.97 millionC$9.33 million-5.95Gap Down
FIRE
The Supreme Cannabis
1.5$0.25-4.0%C$183.67 millionC$49.44 million-1.20
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.39-6.5%C$171.34 millionC$2,360.00-4.95
The Green Organic Dutchman logo
TGOD
The Green Organic Dutchman
0.9$0.35-5.7%C$169.15 millionC$15.36 million-0.38Upcoming Earnings
IVQ
Invesque
1.2$2.98-1.7%C$166.45 millionC$207.60 million-1.17Upcoming Earnings
HTL
Hamilton Thorne
1.4$1.57-11.5%C$165.83 millionC$38.36 million224.29
ONC
Oncolytics Biotech
1.2$3.40-15.0%C$147.22 millionN/A-3.77High Trading Volume
EDT
Spectral Medical
0.5$0.62-1.6%C$146.70 millionC$2.31 million-17.22
EPI
ESSA Pharma
0.6$8.20-6.7%C$145.78 millionN/A-8.27
IPA
ImmunoPrecise Antibodies Ltd. (IPA.V)
0.4$14.71-2.2%C$123.03 millionC$16.70 million-81.72Upcoming Earnings
High Trading Volume
HBP
Helix BioPharma
0.5$0.85-2.4%C$119.96 millionN/A-15.74Upcoming Earnings
WMD
WeedMD
1.3$0.42-2.4%C$95.35 millionC$27.21 million-4.77
PTQ
Protech Home Medical
1.4$1.97-0.0%C$94.56 millionC$82.22 million-51.84Analyst Revision
NINE
Delta 9 Cannabis
0.8$1.03-2.9%C$89.36 millionC$12.87 million19.07Gap Down
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.80-8.8%C$88.79 millionC$81,000.0029.63Gap Down
LXG
LexaGene
0.5$0.97-4.1%C$83.27 millionN/A-10.21Gap Down
CENTRIC HEALTH logo
CHH
CENTRIC HEALTH
0.6$0.23-1,617.4%C$82.18 millionC$125.52 million-2.88Gap Up
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
Trilogy International Partners logo
TRL
Trilogy International Partners
1.3$1.31-4.6%C$77.46 millionC$607.61 million-4.15
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05-0.0%C$76.88 millionC$1.33 million-1.72Upcoming Earnings
FLWR
The Flowr
1.0$0.31-9.7%C$70.01 millionC$5.96 million-0.79
LABS
MediPharm Labs Corp. (LABS.TO)
1.3$0.49-1.0%C$67.70 millionC$62.40 million-1.63
KHRN
Khiron Life Sciences Corp. (KHRN.V)
1.1$0.42-7.1%C$67.34 millionC$8.01 million-1.60High Trading Volume
Gap Down
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
RX
BioSyent Inc. (RX.V)
1.0$7.30-2.7%C$64.81 millionC$22.18 million22.81
MBX
Microbix Biosystems
0.9$0.59-1.7%C$64.57 millionC$11.64 million-11.57Gap Down
SBM
Sirona Biochem
0.5$0.48-5.2%C$58.80 millionC$71,243.00-21.82High Trading Volume
Gap Down
DN
Delta 9 Cannabis
1.4$0.52-0.0%C$53.06 millionC$48.48 million-12.68
SQD
SQI Diagnostics
0.9$0.33-6.1%C$52.59 millionC$977,000.00-9.17Earnings Announcement
PHM
Protech Home Medical
0.5$0.12-4.3%C$50.12 millionC$77.14 million57.50Gap Up
TLT
Theralase Technologies Inc. (TLT.V)
1.0$0.26-1.9%C$49.03 millionC$976,634.00-6.34
IN
InMed Pharmaceuticals Inc. (IN.TO)
0.6$5.50-2.5%C$44.28 millionN/A-3.81
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.